Results 91 to 100 of about 29,994 (144)

RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236. [PDF]

Clin Cancer Res
Pfeil AJ, Zhang T, Cheng R, Mattar MS, Gomez Marti JL, Gili L, Lai R, Khodos I, Master RP, Dix JM, Gazzo A, Arbour KC, de Stanchina E, Febres-Aldana CA, Ladanyi M, Yang SR, Somwar R.   +16 more
europepmc   +1 more source

Molecular features in gangliogliomas: a systematic review. [PDF]

Childs Nerv Syst
Pereira BJA, Oba-Shinjo SM, de Azevedo IKH, Casal YR, Tzu WH, de Almeida AN, Paiva WS, Marie SKN.   +7 more
europepmc   +1 more source

Effect of sex differences on the emergence of ctDNA RAS mutations in RAS wild-type colorectal cancer. [PDF]

Sci Rep
Iguchi K, Uchiyama M, Asari M, Numata K, Shiozawa M.   +4 more
europepmc   +1 more source

Clinico-genomic characterization of RAS-mutant acute myeloid leukemia. [PDF]

Ann Hematol
Yuan R, Xie Y, Miron PM, Higgins AW, Hutchinson L, Cerny J, Patel SA.   +6 more
europepmc   +1 more source

EZR-PLC and RhoGTPases interactions in osteosarcoma pathogenesis and metastatic process [PDF]

, 2014
LEOPIZZI, MARTINA
core   +1 more source

STK38 Kinase Promotes Cell Migration Induced by Oncogenic Ras via MerTK Activation. [PDF]

Int J Mol Sci
Ohta S, Tago K, Kasashima K, Ebina M, Tominaga K.   +4 more
europepmc   +1 more source

Regulation of G1/S Cell Cycle Progression by Transforming Growth Factor-beta [PDF]

, 2003
Zhang, Fan
core  

Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer. [PDF]

Cancer Med
Kim D, Sharif S, Garay JAR, Bhakta AS, Boland PM, Cavnar MJ, Churchman ML, Hatoum H, Huang LC, Kim J, Kim R, Lentz RW, Mukherjee S, O'Donnell MT, Quartey B, Reilley MJ, Rounbehler RJ, Salhia B, Schneider BP, Chan CH.   +19 more
europepmc   +1 more source

Dysregulation of MicroRNAs in Hepatocellular Carcinoma: Targeting Oncogenic Signaling Pathways for Innovative Therapies. [PDF]

Int J Mol Sci
Zarlashat Y, Halász J, Dósa E.
europepmc   +1 more source

KRAS-elicited PDIA6 blocks PERK-dependent immunogenic cell death in pancreatic carcinoma. [PDF]

Oncoimmunology
Zhao L, Liu P, Kroemer G, Kepp O.
europepmc   +1 more source